Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings

robot
Abstract generation in progress

Barclays has raised its price target for Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104, maintaining an Overweight rating, following strong Q1 earnings. The medical device company reported significant growth in Q1 sales and TAVR sales, and increased its FY26 constant currency sales growth and adjusted EPS guidance. Edwards Lifesciences specializes in patient-focused medical innovations for heart disease and critical care monitoring.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin